Frank Kung

Frank C.
Kung is the founder of Cetus Corp.
founded in 1981.
Dr. Kung was the founder of Genelabs Technologies, Inc. founded in 1983 and served as Chairman & Chief Executive Officer from 1983 to 1995.
Dr. Kung is the founder of Vivo Capital LLC founded in 1996 and serves as Managing Partner since 1996.
Dr. Kung currently serves as Chairman at Hamilton Pharmaceuticals, Inc., Director at Copernicus Therapeutics, Inc., and Director at Medeor Therapeutics, Inc. since 2013.
Former positions include Director at Pepgen Corp., Independent Director at Amyris, Inc. from 2017 to 2024, Director at Biotechnology Innovation Organization, Director at Revance Therapeutics, Inc., Director at NextWave Pharmaceuticals, Inc., Director at Sagent Holdings Co. from 2006 to 2011, Director at Nuveta, Inc., Director at West Coast Co., Ltd., Director at Asian American Manufacturers Association, Director at Monte Jade Science & Technology Association, Director at Nanjing King-friend Biochemical Pharmaceutical Co., Ltd., Non-Executive Director at BioDlink International Co., Ltd. from 2016 to 2022, and Independent Director at Sagent Pharmaceuticals, Inc. from 2011 to 2015.
Education includes a doctorate (1976) and MBA (1983) from the University of California, Berkeley, and an undergraduate degree from National Tsing-Hua University in 1970.